万邦德(002082.SZ)：子公司药品WP107获得伦理批件

Core Viewpoint - Wanbangde (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received approval from the Medical Ethics Committee of Wenzhou Medical University Second Affiliated Hospital and Wenzhou Medical University Affiliated Yuying Children's Hospital to conduct Phase I clinical trials for its new drug WP107, which is aimed at treating myasthenia gravis [1] Group 1 - Wanbangde's new drug WP107 is specifically designed for the treatment of myasthenia gravis [1] - The approval for the clinical trial was granted by two medical institutions affiliated with Wenzhou Medical University [1]